vs

Side-by-side financial comparison of ANAVEX LIFE SCIENCES CORP. (AVXL) and ZenaTech, Inc. (ZENA). Click either name above to swap in a different company.

ANAVEX LIFE SCIENCES CORP. is the larger business by last-quarter revenue ($1.1M vs $941.9K, roughly 1.1× ZenaTech, Inc.).

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical firm focused on developing novel small molecule therapeutics for neurodegenerative and neurodevelopmental disorders such as Alzheimer’s disease, Rett syndrome and Parkinson’s disease. It operates mainly across North America and European markets, targeting patients with high unmet medical needs.

ZenaTech, Inc. is a technology firm specializing in AI-integrated drone solutions and enterprise SaaS platforms for industrial and public sector clients. Its core offerings include purpose-built drone hardware, fleet management tools, and actionable data analytics, serving key markets such as public safety, infrastructure inspection, agriculture, and logistics across North America.

AVXL vs ZENA — Head-to-Head

Bigger by revenue
AVXL
AVXL
1.1× larger
AVXL
$1.1M
$941.9K
ZENA

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
AVXL
AVXL
ZENA
ZENA
Revenue
$1.1M
$941.9K
Net Profit
$-5.7M
Gross Margin
Operating Margin
-628.5%
Net Margin
-526.5%
Revenue YoY
-22.6%
Net Profit YoY
53.1%
EPS (diluted)
$-0.06
$-0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVXL
AVXL
ZENA
ZENA
Q4 25
$1.1M
Q3 25
$999.0K
$941.9K
Q2 25
$1.1M
$702.6K
Q1 25
$1.2M
$431.7K
Q4 24
$1.4M
Q3 24
$1.8M
$820.1K
Q2 24
$1.8M
Q1 24
$1.8M
Net Profit
AVXL
AVXL
ZENA
ZENA
Q4 25
$-5.7M
Q3 25
$-9.8M
Q2 25
$-13.2M
Q1 25
$-11.2M
Q4 24
$-12.1M
Q3 24
$-11.6M
Q2 24
$-12.2M
Q1 24
$-10.5M
Operating Margin
AVXL
AVXL
ZENA
ZENA
Q4 25
-628.5%
Q3 25
-1085.5%
Q2 25
-1345.0%
Q1 25
-1034.1%
Q4 24
-975.0%
Q3 24
-810.9%
Q2 24
-813.1%
Q1 24
-718.9%
Net Margin
AVXL
AVXL
ZENA
ZENA
Q4 25
-526.5%
Q3 25
-983.7%
Q2 25
-1231.9%
Q1 25
-925.3%
Q4 24
-868.8%
Q3 24
-660.2%
Q2 24
-680.1%
Q1 24
-600.6%
EPS (diluted)
AVXL
AVXL
ZENA
ZENA
Q4 25
$-0.06
Q3 25
$-0.11
$-0.49
Q2 25
$-0.16
$-0.01
Q1 25
$-0.13
Q4 24
$-0.14
Q3 24
$-0.14
Q2 24
$-0.14
Q1 24
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVXL
AVXL
ZENA
ZENA
Cash + ST InvestmentsLiquidity on hand
$131.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$126.6M
Total Assets
$133.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVXL
AVXL
ZENA
ZENA
Q4 25
$131.7M
Q3 25
$102.6M
Q2 25
$101.2M
Q1 25
$115.8M
Q4 24
$120.8M
Q3 24
$132.2M
Q2 24
$138.8M
Q1 24
$139.4M
Stockholders' Equity
AVXL
AVXL
ZENA
ZENA
Q4 25
$126.6M
Q3 25
$94.9M
Q2 25
$91.0M
Q1 25
$99.8M
Q4 24
$110.9M
Q3 24
$120.3M
Q2 24
$129.8M
Q1 24
$135.0M
Total Assets
AVXL
AVXL
ZENA
ZENA
Q4 25
$133.0M
Q3 25
$103.8M
Q2 25
$102.4M
Q1 25
$117.1M
Q4 24
$124.0M
Q3 24
$135.6M
Q2 24
$141.5M
Q1 24
$144.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVXL
AVXL
ZENA
ZENA
Operating Cash FlowLast quarter
$-7.2M
$-3.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVXL
AVXL
ZENA
ZENA
Q4 25
$-7.2M
Q3 25
$-8.6M
$-3.1M
Q2 25
$-12.5M
$-941.0K
Q1 25
$-5.9M
$-396.2K
Q4 24
$-12.1M
Q3 24
$-6.7M
$-3.1M
Q2 24
$-5.2M
Q1 24
$-11.7M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons